Cargando…
World's First Clinical Case of Gene-Activated Bone Substitute Application
Treatment of patients with large bone defects is a complex clinical problem. We have initiated the first clinical study of a gene-activated bone substitute composed of the collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor. The first patient with two nonunio...
Autores principales: | Bozo, I. Y., Deev, R. V., Drobyshev, A. Y., Isaev, A. A., Eremin, I. I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116519/ https://www.ncbi.nlm.nih.gov/pubmed/27891264 http://dx.doi.org/10.1155/2016/8648949 |
Ejemplares similares
-
Bringing a Gene-Activated Bone Substitute Into Clinical Practice: From Bench to Bedside
por: Bozo, Ilia Y., et al.
Publicado: (2021) -
Ordinary and Activated Bone Grafts: Applied Classification and the Main Features
por: Deev, R. V., et al.
Publicado: (2015) -
Comment on “World's First Clinical Case of Gene-Activated Bone Substitute Application”
por: Rizvanov, Albert A., et al.
Publicado: (2017) -
3D Printing of Octacalcium Phosphate Bone Substitutes
por: Komlev, Vladimir S., et al.
Publicado: (2015) -
Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease
por: Deev, Roman, et al.
Publicado: (2017)